Eli Lilly (NYSE:LLY) Shares Rise After Atai Partnership Could Unlock $1 Billion in Milestones
NEW YORK, July 16, 2026, 5:08 p.m. EDT – Shares of Eli Lilly (NYSE:LLY) edged higher on Thursday after the drugmaker announced a deal with Atai Life Sciences, a partnership that may generate up to $1…
Read the full articleYou might also wanna read
Eli Lilly’s $400 Billion Surge Is Reshaping Big Pharma
Roughly $400 billion. That is how much market value Eli Lilly (NYSE:LLY) has added over the past year, with shares climbing from $773.86 on
Guggenheim Upgrades Eli Lilly (LLY) Price Target Ahead of Q2 Earnings
Guggenheim increases Eli Lilly (LLY) price target to $1,273, projecting Q2 revenue above consensus. Retatrutide success probability raised t
Guggenheim Ups Eli Lilly (LLY) Price Target to $1,273 on Pipeline Strength
Guggenheim raises Eli Lilly (LLY) price target to $1,273, citing strong tirzepatide growth and retatrutide pipeline potential. Q2 earnings e
AtaiBeckley surges after report Lilly poised to buy psychedelic drug developer
July 16 (Reuters) - AtaiBeckley shares soared 50% premarket on Thursday after a report that Eli Lilly was in talks to acquire the psychedeli
Lilly Strikes $3.8 Billion Deal for Psychedelic Drugmaker
Eli Lilly & Co. agreed to buy AtaiBeckley Inc. for as much as $3.8 billion, underscoring growing interest from large drugmakers in the once-
Pharma giant Eli Lilly enters psychedelics space with AtaiBeckley takeover
AtaiBeckley stock rose more than 55% in after-hours trading Wednesday The post Pharma giant Eli Lilly enters psychedelics space with AtaiBec
Comments
Sign in to join the conversation.
No comments yet. Be the first.